CDK9 and B-cell chronic lymphocytic leukemia: While demonstrating features typical of other CDK9 inhibitors, disruption of BCR signaling through the inhibition of Lck and Fyn identified TG02 as a novel dual inhibitor with the potential to target CLL cells both in lymphatic tissue and in circulation.